Puma Biotechnology, INC.
Reporting payments is a legal requirement; large totals often reflect large product portfolios.
$5.8Mgeneral payments (2019-2025)
$16Kresearch payments (2019-2025)
9,684clinicians paid
General and research payments are shown separately, never blended. Research payments are often institution-directed and tied to clinical trials.
General payments by year
General payments only, as reported to CMS. Research payments are totaled above and not included in these bars.
Products most associated with its payments
Specialties it works with most
Clinicians with the largest reported totals
Often long-running consulting, speaking, or advisory relationships, which companies must report by law. A large total is not evidence of anything improper.
| Clinician | Location | Specialty | General payments (2019-2025) |
|---|---|---|---|
| Adrian Senderowicz | Bethesda, MD | Medical Oncology | $1,453,587.57 |
| Anne Odea | Westwood, KS | Medical Oncology | $395,257.88 |
| Michel Velez | Orlando, FL | Medical Oncology | $284,559.92 |
| Brian Leyland Jones | Sioux Falls, SD | Medical Oncology | $181,402.42 |
| Suresh Ratnam | Mcallen, TX | Medical Oncology | $166,596.36 |
| Maria Theodoulou | Albany, NY | Medical Oncology | $163,607.01 |
| Vijayakrishna Gadi | Seattle, WA | Medical Oncology | $162,921.31 |
| Ruemu Birhiray | Indianapolis, IN | Hematology & Oncology | $160,476.36 |
| Francis Arena | Lake Success, NY | Hematology & Oncology | $151,755.65 |
| Jan Van Tornout | Los Angeles, CA | Pediatric Hematology-Oncology | $136,680.00 |
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.